Altimmune, Inc. beat EPS estimates 88% of the time across 16 reported quarters (14 beats, 2 misses), averaging +12.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.15 | $-0.12 | +20.0% | Beat | Q2 FY26 call |
| Q1 FY26 | $-0.25 | $-0.18 | +28.0% | Beat | |
| Q4 FY25 | $-0.25 | $-0.27 | -8.0% | Miss | Q4 FY25 call |
| Q3 FY25 | $-0.29 | $-0.21 | +27.6% | Beat | |
| Q2 FY25 | $-0.32 | $-0.27 | +15.6% | Beat | |
| Q1 FY25 | $-0.35 | $-0.26 | +25.7% | Beat | |
| Q4 FY24 | $-0.34 | $-0.33 | +2.9% | Beat | |
| Q3 FY24 | $-0.36 | $-0.32 | +11.1% | Beat | |
| Q2 FY24 | $-0.34 | $-0.35 | -2.9% | Miss | |
| Q1 FY24 | $-0.36 | $-0.34 | +5.6% | Beat | |
| Q4 FY23 | $-0.35 | $-0.33 | +5.7% | Beat | |
| Q3 FY23 | $-0.40 | $-0.39 | +2.5% | Beat |
Back to ALT overview · ALT holders · ALT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.